PET scans with 68Ga-Galmydar to spot heart damage from chemotherapy
Tests 68Ga-Galmydar PET scans for heart damage in adults with breast cancer or lymphoma.
Plain-language title generated from the registry record
Registry title: Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
Key facts
- Where
- St Louis, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 99 years old?
Source: NCT07838649, who can take part
Where in United States
- Washington University School of MedicineSt Louis, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT07838649
- Record updated
- 24 September 2026
- Original description
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.Read full original descriptionShow less
PET Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or lymphoma undergoing treatment with anthracycline for cancer therapy.
Inclusion: Men and women, 21-99 years of age and any race; Normal left ventricular function (left ventricular ejection fraction (LVEF) >50%) as determined by echocardiography; HER2 positive or negative breast cancer patients or lymphoma patients; Designated to receive standard of care (SOC) treatment with an anthracycline-containing regimen including combination therapy; Patients willing to adhere to fasting for 15 hours before 18F-FDG PET imaging studies (if applicable).
Exclusion: Prior exposure to anthracyclines or other cardiotoxic drug; Contraindications to anthracycline chemotherapy; Contraindications to MR imaging (ferromagnetic implants, pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.); Patients with history of myocardial infarction; Any condition that in the opinion of the Principal Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as:; Inability to lie still or unable to tolerate a supine position with arms up over the head or down at sides for up to a 60-minute PET scan due to chronic back/shoulder pain or arthritis as assessed by physical examination and/or medical history; Patients with fasting blood sugar >200 mg/dL or <70 mg/dL and symptomatic; Pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 68Ga-Galmydar or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy; Inability to receive and sign informed consent.